Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
复制标题
DOI：
10.1016/j.vaccine.2021.10.007
复制
发表时间：
2021-11-05
期刊：
影响因子：
5.5
通讯作者：
Rahman Bizri A
中科院分区：
文献类型：
--
作者：
Moghnieh R;Mekdashi R;El-Hassan S;Abdallah D;Jisr T;Bader M;Jizi I;Sayegh MH;Rahman Bizri A
面对新的新冠肺炎浪潮，人们注意到，在那些已经接种了两剂疫苗的国家，BBIBP-COV的有效性较低。与同种免疫相比，CHAdOx1-S/BNT162b2异种免疫具有更高的免疫原性。BBIBP-CORV/BNT162b2组合值得试验。在这项于2021年2月17日至2021年6月30日在黎巴嫩贝鲁特马卡萨斯综合医院进行的试验性前瞻性队列研究中，我们在接种了两剂BBIBP-COV疫苗的幼稚新冠肺炎患者中测试了BNT162b2强化剂量的安全性和免疫原性。异种加强免疫是安全和耐受性良好的。与同源BNT162b2免疫后相比，新冠肺炎幼稚个体的抗体几何平均滴度显著升高[分别为(8040BAU/mL，95%可信区间，4612-14,016)vs(1384BAU/mL，95%可信区间，1063-1801，P<0.0001)]。在获得信使核糖核酸疫苗的机会有限的国家，以及人口已经接种BBIBP-Corv的国家，混合BBIBP-Corv/BNT162b2被认为可以克服BBIBP-Corv单独诱导的低免疫原性，从而潜在地提供对新出现的变种的保护。
Facing new COVID-19 waves, the effectiveness of BBIBP-CorV has been noted to be low in countries whose populations were already administered two doses of the vaccine. Heterologous vaccination using ChAdOx1-S/BNT162b2 elicited higher immunogenicity compared with homologous immunization. BBIBP-CorV/BNT162b2 combination is worth testing. In this pilot prospective cohort study conducted at Makassed General Hospital, Beirut, Lebanon, from February 17, 2021, to June 30, 2021, we tested the safety and immunogenicity of a BNT162b2 booster dose in COVID-19-naïve individuals who had received two doses of the BBIBP-CorV vaccine. Heterologous booster vaccination was found to be safe and well tolerated. It was significantly associated with higher anti-spike IgG geometric mean titers compared to that after homologous BNT162b2 immunization in COVID-19-naïve individuals [(8040 BAU/mL, 95% confidence interval (CI), 4612–14 016) vs (1384 BAU/mL, 95% CI, 1063–1801), respectively, (P < 0.0001)]. In countries with limited access to mRNA vaccines and where populations have already received BBIBP-CorV, mixing BBIBP-CorV/BNT162b2 is seen to overcome the low immunogenicity induced by BBIBP-CorV alone, thus potentially providing protection against emerging variants.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1038/s41577-021-00592-1
发表时间：
2021-10
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
Tregoning JS;Flight KE;Higham SL;Wang Z;Pierce BF
通讯作者：
Pierce BF
DOI：
10.1016/j.cmi.2021.01.005
发表时间：
2021-01-20
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
L'Huillier AG;Meyer B;Andrey DO;Arm-Vernez I;Baggio S;Didierlaurent A;Eberhardt CS;Eckerle I;Grasset-Salomon C;Huttner A;Posfay-Barbe KM;Royo IS;Pralong JA;Vuilleumier N;Yerly S;Siegrist CA;Kaiser L;Geneva Centre for Emerging Viral Diseases
通讯作者：
Geneva Centre for Emerging Viral Diseases
DOI：
10.1016/s0140-6736(21)01420-3
发表时间：
2021-07-10
期刊：
Lancet (London, England)
影响因子：
--
作者：
Borobia AM;Carcas AJ;Pérez-Olmeda M;Castaño L;Bertran MJ;García-Pérez J;Campins M;Portolés A;González-Pérez M;García Morales MT;Arana-Arri E;Aldea M;Díez-Fuertes F;Fuentes I;Ascaso A;Lora D;Imaz-Ayo N;Barón-Mira LE;Agustí A;Pérez-Ingidua C;Gómez de la Cámara A;Arribas JR;Ochando J;Alcamí J;Belda-Iniesta C;Frías J;CombiVacS Study Group
通讯作者：
CombiVacS Study Group
灭活的SARS-COV-2疫苗的安全性和免疫原性，BBIBP-CORV：随机，双盲，安慰剂对照，1/2期试验。
DOI：
10.1016/s1473-3099(20)30831-8
发表时间：
2021-01
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Xia S;Zhang Y;Wang Y;Wang H;Yang Y;Gao GF;Tan W;Wu G;Xu M;Lou Z;Huang W;Xu W;Huang B;Wang H;Wang W;Zhang W;Li N;Xie Z;Ding L;You W;Zhao Y;Yang X;Liu Y;Wang Q;Huang L;Yang Y;Xu G;Luo B;Wang W;Liu P;Guo W;Yang X
通讯作者：
Yang X